Advantage Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due May 7 to 19, 2027 · next May 7
- 2 fees due Jul 2 to 9, 2027 · next Jul 2
- 1 fee due Nov 12, 2027The maintenance fee for Treatment of Alzheimer's Disease (AD) with an Aluminum Salt (US 10,646,565) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,478,454 | Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide In force · From the USPTO record | In force | From the USPTO record | |
| US 10,646,565 | Treatment of Alzheimer's Disease (AD) with an Aluminum Salt In force · Medium confidence | In force | Medium confidence | |
| US 11,065,273 | Treatment and prevention of alzheimer's disease (AD) In force · From the USPTO record | In force | From the USPTO record | |
| US 11,147,873 | Treatment of Alzheimer's Disease (AD) with an Aluminum Salt In force · Medium confidence | In force | Medium confidence | |
| US 11,857,568 | Treatment and prevention of Alzheimer's disease (AD) In force · From the USPTO record | In force | From the USPTO record | |
| US 11,866,469 | DNA Binding Proteins and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,807,850 | Compositions and Methods for Modulating Gene Expression In force · High confidence | In force | High confidence | |
| US 12,134,772 | Increasing Gene Expression In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 no status recorded